Ifedayo Adetifa/Vaccine

WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.Sparrow, E. Adetifa, I. Chaiyakunapruk, N. Cherian, T. Fell, D. B. Graham, B. S. Innis, B. Kaslow, D. C. Karron, R. A. Nair, H. Neuzil, K. M. Saha, S. Smith, P. G. Srikantiah, P. Were, F. Zar, H. J. Feikin, D.
Vaccine, (2022). 40:3506-3510

Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data.Ojal, J. Flasche, S. Hammitt, L. L. Akech, D. Kiti, M. C. Kamau, T. Adetifa, I. Nurhonen, M. Scott, J. A. G. Auranen, K.
Vaccine, (2017). 35:4561-4568